Part I. Biochemical Approaches, In vitro and In vivo
1. Approaches to Detect PARP-1 Activation In vivo, In situ, and In vitro
Girsih M. Shah, Febitha Kandan-Kulangara, Alicia Montoni, Rashmi G. Shah, Julie Brind'Amour, Momchil D. Vodenicharov, and El Bachir Affar
2. Quantification of Poly(ADP-ribose) In vitro: Determination of the (ADP-ribose) Chain Length and Branching Pattern
Rafael Alvarez-Gonzalez and Myron K. Jacobson
3. Assay for Protein Modification by Poly-ADP-Ribose In vitro
Opeyemi A. Olabisi and Chi-Wing Chow
4. Identification of Distinct Amino Acids as ADP-ribose Acceptor Sites by Mass Spectrometry
Florian Rosenthal, Simon Messner, Bernd Roschitzki, Peter Gehrig, Paolo Nanni, and Micahel O. Hottiger
5. Non-covalent Protein Interaction with Poly(ADP-ribose)
Maria Malanga and Felix R. Althaus
6. Non-covalent pADPr Interaction with Protein and Competition with RNA for Binding to Proteins
Yingbiao Ji
7. Affinity-based Assays for the Identification and Quantitative Evaluation of Non-covalent Poly(ADP-ribose)-binding Proteins
Jean-Phillipe Gagné, Jean-François Haince, Émilie Pic, and Guy G. Poirier
8. Detecting and Quantifying pADPr In vivo
Yi-Chen Lai, Rajesh K. Aneja, Margaret A. Satchell, and Robert S. B. Clark
9. Purification of Recombinant Poly(ADP-ribose) Polymerases
Jean-Christophe Amé, Thomas Kalish, Françoise Dantzer, and Valérie Schreiber
10. Methods for Purification of Proteins Associated with Cellular poly(ADP-risbose) and PARP-specific Poly(ADP-ribose)
Jennifer E. Rood, Anthony K. L. Leung, and Paul Chang
11. Purification and Characterization of Poly(ADP-ribosyl)ated DNA Replication/Repair Complexes
Cynthia M. Simbulan-Rosenthal, Dean S. Rosenthal, and Mark E. Smulson
12. PARP1 Genomics: Chromatin Immuno-precipitation Approach using Anti-PARP1 Antibody (ChIP and ChIP-seq)
Niraj Lodhi and Alexei V. Tulin
13. Purification of Human PARP-1 and PARP-1 Domains from E. coli for Structural and Biochemical Analysis
Marie-France Langelier, Jamie L. Planck, Kristin M. Servent, and John M. Pascal
14. Regulation of Chromatin Structure by PARP-1
MiYoung Kim
Part II. Genetic Manipulation Approaches
15. The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients; Techniques used to Identify Susceptible Agents
Sydney Shall, Terry Gaymes, Farzin Farzaneh, Nicola Curtin, and Ghulam J. Mufti
16. Quantification of PARP Activity in Human Tissues: Ex vivo Assays in Blood Cells, and Immunohistochemistry in Human Biopsies
Eszter M. Horvath, Zsuzsanna K. Zsengellér, and Csaba Szabo
17. Assay for Hypermethilation of the BRCA1 Gene Promoter in Tumor Cells to Predict Sensitivity to PARP-Inhibitor Therapy
Ilsiya Ibragimova and Pauls Cairns
18. Generation of Poly(ADP-ribosyl)ation Deficient Mutants of the Transcription Factor, CTCF
Dawn Farrar, Igor Chernukhin, and Elena Klenova
19. Phenotypic Characterization of Parp-1 and Parp-2 Deficient Mice and Cells
Christian Boehler, Laurent Gauthier, Jose Yelamos, Aurélia Noll, Valérie Schreiber, and Françoise Dantzer
20. Poly(ADP-ribosyl)ation Pathways in Mammals: The Advantage of Murine PARG Null Mutation
Yiran Zhou and David W. Koh
21. Genetic Approaches to Targeti
